AAAAAA
Results:
1-16
|
Results: 16
Authors:
Gruaz-Guyon, A
Janevik-Ivanovska, E
Raguin, O
De Labriolle-Vaylet, C
Barbet, J
Citation: A. Gruaz-guyon et al., Radiolabeled bivalent haptens for tumor immunodetection and radioimmunotherapy, Q J NUCL M, 45(2), 2001, pp. 201-206
Authors:
Gestin, JF
Loussouarn, A
Bardies, M
Gautherot, E
Gruaz-Guyon, A
Sai-Maurel, C
Barbet, J
Curtet, C
Chatal, JF
Faivre-Chauvet, A
Citation: Jf. Gestin et al., Two-step targeting of xenografted colon carcinoma using a bispecific antibody and Re-188-labeled bivalent hapten: Biodistribution and dosimetry studies, J NUCL MED, 42(1), 2001, pp. 146-153
Authors:
Tran, A
Treluyer, JM
Rey, E
Barbet, J
Ferracci, G
d'Athis, P
Vincent, J
Pons, G
Citation: A. Tran et al., Protective effect of stiripentol on acetaminophen-induced hepatotoxicity in rat, TOX APPL PH, 170(3), 2001, pp. 145-152
Authors:
de Labriolle-Vaylet, C
Cattan, P
Sarfati, E
Wioland, M
Billotey, C
Brocheriou, C
Rouvier, E
de Roquancourt, A
Rostene, W
Askienazy, S
Barbet, J
Milhaud, G
Gruaz-Guyon, A
Citation: C. De Labriolle-vaylet et al., Successful surgical removal of occult metastases of medullary thyroid carcinoma recurrences with the help of immunoscintigraphy and radioimmunoguidedsurgery, CLIN CANC R, 6(2), 2000, pp. 363-371
Authors:
Karacay, H
McBride, WJ
Griffiths, GL
Sharkey, RM
Barbet, J
Hansen, HJ
Goldenberg, DM
Citation: H. Karacay et al., Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a Tc-99m-Re-188-labeled peptide, BIOCONJ CHE, 11(6), 2000, pp. 842-854
Authors:
de Boisferon, MH
Raguin, O
Dussaillant, M
Rostene, W
Barbet, J
Gruaz-Guyon, A
Citation: Mh. De Boisferon et al., Enhanced targeting specificity to tumor cells by simultaneous recognition of two antigens, BIOCONJ CHE, 11(4), 2000, pp. 452-460
Authors:
Hosono, MN
Hosono, M
Mishra, AK
Faivre-Chauvet, A
Gautherot, E
Barbet, J
Knapp, FF
Chatal, JF
Citation: Mn. Hosono et al., Rhenium-188-labeled anti-neural cell adhesion molecule antibodies with 2-iminothiolane modification for targeting small-cell lung cancer, ANN NUCL M, 14(3), 2000, pp. 173-179
Authors:
Gautherot, E
Rouvier, E
Daniel, L
Loucif, E
Bouhou, J
Manetti, C
Martin, M
Le Doussal, JM
Barbet, J
Citation: E. Gautherot et al., Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and I-131-labeled bivalent hapten, J NUCL MED, 41(3), 2000, pp. 480-487
Authors:
Pelegrin, A
Xavier, F
Barbet, J
Bartholeyns, J
Baty, D
Buchegger, F
Chatal, JF
Dubief, F
Guerreau, D
Gruaz-Guyon, A
Lamotte, D
Leserman, L
Mach, JP
Robert, B
Saccavini, JC
Teillaud, JL
Teulon, I
Citation: A. Pelegrin et al., Immunotargeting of tumors: state of the art and prospects in 2000, B CANCER, 87(11), 2000, pp. 777-791
Authors:
Barbet, J
Kraeber-Bodere, F
Vuillez, JP
Gautherot, E
Rouvier, R
Chatal, JF
Citation: J. Barbet et al., Pretargeting with the Affinity Enhancement System for radioimmunotherapy, CANC BIO R, 14(3), 1999, pp. 153-166
Authors:
Gautherot, E
Kraeber-Bodere, F
Daniel, L
Fiche, M
Rouvier, E
Sai-Maurel, C
Thedrez, P
Chatal, JF
Barbet, J
Citation: E. Gautherot et al., Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with I-131-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody, CLIN CANC R, 5(10), 1999, pp. 3177S-3182S
Authors:
Kraeber-Bodere, F
Faivre-Chauvet, A
Sai-Maurel, C
Campion, L
Fiche, M
Gautherot, E
Le Boterff, J
Barbet, J
Chatal, JF
Thedrez, P
Citation: F. Kraeber-bodere et al., Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: Comparison of iodine 131-labeled F(ab ')(2) and pretargeted bivalent hapten and evaluation of repeated injections, CLIN CANC R, 5(10), 1999, pp. 3183S-3189S
Authors:
Kraeber-Bodere, F
Bardet, S
Hoefnagel, CA
Vieira, MR
Vuillez, JP
Murat, A
Ferreira, TC
Bardies, M
Ferrer, L
Resche, I
Gautherot, E
Rouvier, E
Barbet, J
Chatal, JF
Citation: F. Kraeber-bodere et al., Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: Preliminary results of a phase I/II clinical trial, CLIN CANC R, 5(10), 1999, pp. 3190S-3198S
Authors:
Vuillez, JP
Kraeber-Bodere, F
Moro, D
Bardies, M
Douillard, JY
Gautherot, E
Rouvier, E
Barbet, J
Garban, F
Moreau, P
Chatal, JF
Citation: Jp. Vuillez et al., Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: Results of a phase I/II trial, CLIN CANC R, 5(10), 1999, pp. 3259S-3267S
Authors:
Hosono, M
Hosono, MN
Kraeber-Bodere, F
Devys, A
Thedrez, P
Faivre-Chauvet, A
Gautherot, E
Barbet, J
Chatal, JF
Citation: M. Hosono et al., Two-step targeting and dosimetry for small cell lung cancer xenograft withanti-NCAM/antihistamine bispecific antibody and radioiodinated bivalent hapten, J NUCL MED, 40(7), 1999, pp. 1216-1221
Authors:
Kraeber-Bodere, F
Faivre-Chauvet, A
Sai-Maurel, C
Gautherot, E
Fiche, M
Campion, L
Le Boterff, J
Barbet, J
Chatal, JF
Thedrez, P
Citation: F. Kraeber-bodere et al., Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft, J NUCL MED, 40(1), 1999, pp. 198-204
Risultati:
1-16
|